🟢 Cybin is trading 7.6% up today after Michael Halstead became CEO

Cybin is trading 7.6% up at $11.33, extending gains after Michael Halstead became chief executive officer effective immediately.

• Halstead previously led Intra-Cellular Therapies and was involved in its nearly $15 billion acquisition by Johnson & Johnson, bolstering confidence in Cybin’s late-stage development and commercialization strategy.
• The company-specific catalyst comes as shares rise 13.47% on August 5 and 15.14% on August 4; broader indexes are modestly mixed.
• Investors await Phase 3 APPROACH trial topline results for HLP003 in the fourth quarter of 2026.